TrialHuman vaccines & immunotherapeutics2024

A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016).

Andrea Guerra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.